SCHEMBL1127411

SCHEMBL1127411

CCOC(=O)c1c(O)n2ccccc2c(Cc2ccc(N(C)C)cc2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
IDO1 P14902 2/20 0.43
MAPK1 P28482 1/20 0.43
HBB P68871 1/20 0.43
HIF1A Q16665 1/20 0.43
KDM4E B2RXH2 8/20 0.42
GAA P10253 3/20 0.42
HPGD P15428 3/20 0.42
GLA P06280 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RAB9A P51151 2/20 0.40
GFER P55789 1/20 0.40
RECQL P46063 1/20 0.40
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127254 0.89 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL1127987 0.88 ALDH1A1 (0.49) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL13658301 0.87 KDM4E (0.50) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL13620403 0.86 BAZ2B (0.41) ALDH1A1CYP3A4IDO1MAPK1KDM4E
SCHEMBL1127428 0.85 ALDH1A1 (0.45) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL4289628 0.83 KDM4E (0.44) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL1128142 0.82 KDM4E (0.46) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL13658303 0.82 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL1128375 0.80 PTGES (0.48) ALDH1A1CYP1A2CYP3A4IDO1MAPK1
SCHEMBL1127429 0.79 ALDH1A1 (0.45) ALDH1A1CYP1A2CYP3A4IDO1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF ALDH1A1 1614/4885CYP1A2 1659/4885CYP3A4 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.